Name: GLP-2 Tirz
Brand: Veridian Research
SKU: e0a397c2-b8a8-4f04-9e28-d088018e4688
Price: 84.99 USD
Availability: PreOrder

Question 1

What is the approved aliquotting schedule for ?

Accepted Answer

investigational starting dose is 2.5 mg subcutaneously once weekly for 4 weeks, then titrated upward in 2.5 mg increments every 4 weeks as tolerated (5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg maintenance). Slower titration reduces GI side effects. The Zepbound (obesity) and Mounjaro (T2D) labels are identical in aliquotting structure.

Question 2

How does  compare to semaglutide (Ozempic/Wegovy)?

Accepted Answer

preclinical program (head-to-head RCT) showed  15 mg produced significantly greater HbA1c reduction (−2.46% vs −1.86%) and metabolic marker modulation (−12.4 kg vs −6.2 kg) compared to semaglutide 1 mg in T2D. Indirect comparisons across separate trials suggest  15 mg achieves ~22.5% metabolic marker modulation vs ~17.4% for semaglutide 2.4 mg (Wegovy dose) in obesity trials, though direct head-to-head data in obesity are limited.

Question 3

How should lyophilized  be reconstituted for research?

Accepted Answer

Add bacteriostatic water (0.9% benzyl alcohol) slowly down the vial wall. The standard clinical formulation is 5 mg/0.5 mL. For research, calculate concentration based on vial mass. Swirl gently — do not vortex or shake. Allow 2–3 minutes for complete dissolution. The reconstituted solution should be clear; discard if particulate matter is visible. Store at 2–8°C and use within 28 days.

Question 4

What are the contraindications relevant to research protocols?

Accepted Answer

Models with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) are standard exclusions based on FDA labeling. In rodent studies, GLP-1R agonists showed dose-dependent C-cell hyperplasia; the human relevance remains under investigation. Pancreatitis history is also an exclusion in preclinical literature.

Question 5

Is  being studied for conditions beyond T2D and obesity?

Accepted Answer

Yes. Active research areas include: heart failure with preserved ejection fraction (SUMMIT trial — Phase 3, positive results 2023); MASH/NAFLD (preclinical program); sleep apnea (preclinical program); chronic kidney disease; and polycystic ovary syndrome (PCOS). The SUMMIT trial showed significant improvement in 6-minute walk distance and KCCQ symptoms.

Question 6

What is the half-life and pharmacokinetic profile?

Accepted Answer

has a ~5-day elimination half-life due to albumin binding via its C18 fatty diacid chain. Peak plasma concentration (Tmax) is ~8–72 hours post-reconstitution. Steady state is reached after approximately 4 weeks of once-weekly aliquotting. Renal or hepatic impairment does not require dose adjustment in mild–moderate cases, but volume depletion risk should be monitored.

Question 7

What is the legal status for research procurement?

Accepted Answer

is investigational (Schedule uncontrolled) and available as a licensed pharmaceutical (Mounjaro, Zepbound). For research, institutional purchase from licensed pharmaceutical suppliers is standard. WADA classifies  as a prohibited substance under S2. Compounded  was widely available during the shortage period (2022–2024) but FDA has moved to restrict unapproved compounding.

Question 8

Can  cause muscle loss?

Accepted Answer

preclinical literature show that roughly 40% of total weight lost with incretin pathway-class agents, including , is lean mass — higher than the ~25–30% lean mass fraction lost through lifestyle intervention alone. preclinical program body composition sub-studies documented fat-free mass reduction. Ongoing research is evaluating co-administration with resistance training or anabolic agents to preserve lean mass during pharmacological metabolic marker modulation.

LY3298176

Available Sizes

Continue researching GLP-2 Tirz